Feedback
Settings

Settings

Goto Application

8,237 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(ZXIATBNUWJBBGT-JXOAFFINSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 824
1.WO/2025/122721CHIMERIC PROTEINS AND USES THEREOF
WO - 12.06.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/US2024/058632 Applicant SHATTUCK LABS, INC. Inventor SCHREIBER, Taylor
The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
2.WO/2025/119162METAPNEUMOVIRUS (MPV) VACCINE
WO - 12.06.2025
Int.Class C12N 15/45
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
45Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
 Appl.No PCT/CN2024/136380 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided is a metapneumovirus (MPV) vaccine. Specifically, provided is a nucleic acid comprising a polynucleotide for encoding a mutant of an MPV F protein, compared with a wild-type MPV F protein, the mutant comprises a disulfide bond mutation.
3.WO/2025/122628CIRCULARIZED RNAS AND METHODS OF MAKING THE SAME
WO - 12.06.2025
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
 Appl.No PCT/US2024/058479 Applicant HELIX NANOTECHNOLOGIES INC Inventor SAUCEDA, Arianna Lizeth Lopez
The present disclosure provides methods of circularizing RNA using RNA ligase. The present disclosure also provides polyribonucleotides that can be useful in such methods. Such polyribonucleotides can comprise a 5' end comprising a 5'- most nucleotide, a 3' end comprising a 3'- most nucleotide, a first hybridization region and a second hybridization region, wherein the ribonucleotide sequence of the second hybridization region is a reverse complement of the ribonucleotide sequence of the first hybridization region.
4.WO/2025/112200RABIES VACCINE IMMUNOGEN COMPOSITION
WO - 05.06.2025
Int.Class C12N 15/47
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
47Rhabdoviridae, e.g. rabies viruses, vesicular stomatitis virus
 Appl.No PCT/CN2024/076204 Applicant ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY Inventor XU, Jianqing
An anti-rabies virus immunogen composition capable of simultaneously inducing a humoral immune response and a cellular immune response and a use thereof. The anti-rabies virus immunogen composition involves a dual-immunogen combination, comprising a rabies virus glycoprotein G as an immunogen for activating neutralizing antibodies and a polymerase large protein L as a T-cell immunogen. The rabies virus glycoprotein is derived from the full length of a glycoprotein or extracellular region amino acids thereof or an antigenic fragment thereof, and the T-cell immunogen is derived from a recombinant sequence of a conserved region of a polymerase large protein. Optionally, the two immunogens are loaded onto the same type of carrier or different types of carriers. The vaccine is safe and can simultaneously activate anti-rabies virus T cells and an antibody response, thereby realizing combined protection for preventing and treating rabies virus infection.
5.WO/2025/117969PROCESS FOR MANUFACTURING LIPID NANOPARTICLES
WO - 05.06.2025
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/US2024/058122 Applicant ORNA THERAPEUTICS, INC. Inventor JOSHI, Ujjwal
The present application provides methods for manufacturing lipid nanoparticles. The present disclosure provides methods of preparing empty lipid nanoparticles (empty LNPs). The present disclosure provides methods of preparing loaded lipid nanoparticles (loaded LNPs) associated with a nucleic acid. Empty and loaded LNP compositions prepared by the subject methods are also provided. There is provided a homogeneous LNP composition of empty or loaded LNPs of particularly favorable average particle size and poly dispersity index.
6.WO/2025/117732LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF
WO - 05.06.2025
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/US2024/057736 Applicant AKAGERA MEDICINES, INC. Inventor DRUMMOND, Daryl C.
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
7.WO/2025/117815LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF AND METHOD FOR QUANTIFYING AN AMOUNT OF CAPPED MESSENGER RNA
WO - 05.06.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/US2024/057849 Applicant RECODE THERAPEUTICS, INC. Inventor HENNIG, Mirko
Provided are lipid nanoparticles compositions comprising a payload, a helper lipid, a sterol, a PEG-lipid, an ionizable lipid, a permanently cationic lipids. Also provided herein are a method of delivering a payload to a cell in a lung of a subject by intravenous administration and a method for treating and/or preventing a lung disease in a subject in need thereof by intravenous administration. Also provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.
8.WO/2025/116570NOVEL RECOMBINANT ANTIBODY SPECIFICALLY BINDING TO B CELL ANTIGEN, AND USE THEREOF
WO - 05.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/KR2024/019179 Applicant UIF (UNIVERSITY INDUSTRY FOUNDATION), YONSEI UNIVERSITY Inventor KIM, Joo Young
The present invention relates to: a recombinant polypeptide specifically binding to B cells; and a composition for preventing or treating B cell lymphoma, comprising same as an active ingredient. The present invention can significantly improve direct killing activity against tumor cells by conjugating concanavalin A, which is a ligand of MPZL1, to an antibody molecule that recognizes a B cell-specific antigen such as CD20. Therefore, unlike therapeutic antibodies having main mechanisms of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADP), the recombinant polypeptide of the present invention does not depend on operating mechanisms of patient immune systems, and thus can be effectively used in an effective therapeutic composition even for cancer patients with reduced immune activity.
9.WO/2025/117816LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF
WO - 05.06.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/US2024/057850 Applicant RECODE THERAPEUTICS, INC. Inventor KALIYAPERUMAL, Arunan
Disclosed herein are lipid nanoparticles (LNPS) and pharmaceutical compositions and vaccines comprising same. Also disclosed herein are methods of administering an LNP composition, pharmaceutical compositions, and vaccines described herein for preventing an infectious disease and/or for immunizing a subject or for delivering a payload to a cell in the central nervous system (CNS) of a subject. Also provided are methods for treating and/or preventing a CNS disease.
10.WO/2025/117877CAS NUCLEASES AND RELATED METHODS
WO - 05.06.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/US2024/057946 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor TIAN, Pengfei
Provided herein are Cas nucleases (e.g., endonucleases, nickases, etc.) (and functional fragments, functional variants, and domains thereof), nucleic acid molecules encoding the same, and systems comprising the same. The disclosure further relates to methods of utilizing the Cas nucleases (e.g., endonucleases, nickases, etc.) (or nucleic acid molecules encoding the same), including, e.g., in methods of editing a nucleic acid molecule (e.g., a gene) and methods of treating diseases (e.g., genetic diseases).
# -